NCT07069400 An International Observational Study of Adults With Acute Infection
| NCT ID | NCT07069400 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Infectious Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2027-06-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-08-25 with a primary completion date of 2027-06-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective, longitudinal studies of people with acute infections are essential to understand risk factors, clinical manifestations, pathobiology, and management strategies. Observational studies can provide data necessary to select interventions and strategies for testing in clinical trials and to develop key design features of trials. Observational studies can be particularly important for establishing an early knowledge base after emergence of a new pathogen, as illustrated by the recent emergence of influenza A (H1N1), SARS-CoV-2, and Mpox. This observational study protocol describes collection of data and biospecimens from sites across the world for characterizing acute infections in hospitalized patients. The protocol is designed to study respiratory infections, infections outside the respiratory tract, established infectious diseases, and emerging infectious diseases. Data generated in this study will be used to efficiently characterize acute infectious diseases and plan future clinical trials.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old * Admitted to hospital (or in an emergency department with anticipated hospital admission) for the management of a suspected or confirmed acute infectious disease. * Onset of symptoms of an infectious disease within the past 30 days. * Informed consent for study participation by the participant or a surrogate decision maker if the participant lacks capacity for consent. Exclusion Criteria: * Current imprisonment (this does not include quarantine for an infectious disease). * Patient undergoing comfort care measures only such that treatment focuses on end- of-life symptom management over prolongation of life. * Expected inability or unwillingness to participate in study procedures. * In the opinion of the investigator, participation in the study is not in the best interest of the patient.
Contact & Investigator
Cavan Reilly, PhD
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07069400 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infectious Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07069400 currently recruiting?
Yes, NCT07069400 is actively recruiting participants. Contact the research team at webe0376@umn.edu for enrollment information.
Where is the NCT07069400 trial being conducted?
This trial is being conducted at Tucson, United States, Palo Alto, United States, San Francisco, United States, Orlando, United States and 11 additional locations.
Who is sponsoring the NCT07069400 clinical trial?
NCT07069400 is sponsored by University of Minnesota. The principal investigator is Cavan Reilly, PhD at University of Minnesota. The trial plans to enroll 1,500 participants.